Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum Carbonate for Secondary Hyperoxaluria and Nephrolithiasis
NCT03346369Phase 3Completed
- Sponsor
- UZ Brussel
- Start
- Aug 2017
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanthanum carbonate in secondary hyperoxaluria and nephrolithiasis, sponsored by UZ Brussel. Primary endpoint: Mean reduction in urinary oxalate excretion at 2 weeks. Started Aug 2017; status: completed.
02
Drugs
lanthanum carbonate
03
Conditions
secondary hyperoxalurianephrolithiasis
Beyond the preview
Go deeper on NCT03346369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346369.